

## PROGRESSIVE'S EVENING STROLL

DATE: 25 April, 2025

### Market Snapshot:

The Index struggled to sustain its opening gains as a sharp decline in the broader markets added pressure, causing it to trade lower. However, a gradual recovery in the second half helped limit the downside, with the Index eventually settling the day at 24,039.35 with a loss of 207.35 points. Barring IT, all the sectors ended the trade in red, with Media and Realty being the major laggards. The Midcap and Smallcap segments witnessed significant correction, each falling over 2%, underperforming the Frontline Index.

### HOW THE DAY TRENDED



INDICES			
Index	Close	Points	%Chg.
Sensex	79212.53	(588.90)	(0.74)
Nifty50	24039.35	(207.35)	(0.86)
Nifty Midcap 100	53570.20	(1399.65)	(2.55)
Nifty Small Cap 100	16547.20	(416.30)	(2.45)

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	%Chg.
NIFTY IT	35562.25	255.15	0.72
NIFTY PSU BANK	6535.50	(149.90)	(2.24)
NIFTY REALTY	859.35	(24.80)	(2.80)
NIFTY MEDIA	1547.75	(51.75)	(3.24)

NIFTY TOP GAINERS / LOSERS					
Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
SBI LIFE	1695.10	5.40	SHRIRAM FINANCE	655.20	(5.95)
TCS	3448.00	1.36	ADANI ENT	2354.30	(3.61)
TECH MAHINDRA	1462.00	1.16	ADANI PORT	1193.00	(3.51)
ULTRATECH	12237.00	0.64	AXIS BANK	1166.30	(3.38)

### INDICES LEVELS FOR April 28, 2025

Nifty (future)	
Resistance	24360
Support	23980

Bank Nifty (future)	
Resistance	55200
Support	54400



**PROGRESSIVE'S EVENING STROLL**

**DATE: 25 April, 2025**

**KEY TAKEAWAYS OF THE DAY**

◆ **CONCOR and GAIL sign MoU to develop LNG infrastructure:**

The company has signed an MoU with Ministry of Railways, GAIL (India) Ltd and Ministry of Petroleum & Natural Gas to develop LNG infrastructure at various terminals of Concor on a pan India basis.

◆ **Lupin received USFDA nod for Tolvaptan tablets:**

The company has received approval from USFDA for its ANDA for Tolvaptan tablets, used to slowdown kidney function decline. The company said it is the exclusive first-to-file for the product and eligible for 180 days of generic exclusivity. The drug will be manufactured at the Lupin's facility in Nagpur and will be launched soon. Tolvaptan slows down the deterioration of kidney function in adults who are at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). The tablets had an annual sale of nearly USD1.47bn in US in 2024.

◆ **Bannari Amman approved Rights Issue of 15mn shares at Rs27 each, raising Rs407.1mn:**

The Board has approved rights issue of 15,079,504 equity shares of FV of Rs5 each for an aggregate amount of approx. Rs400mn at an issue price of Rs27 per equity share. The rights entitlement ratio is set as 10 rights equity shares for every 43 held as on the record date.

◆ **Minor fire at BHEL, Bhopal contained quickly; no damage or injuries reported:**

A minor fire broke out at the company's Bhopal facility. The fire was swiftly brought under control by the CISF fire team, with assistance from municipal fire services and the State Disaster Response Fund (SDRF).

◆ **Patel Engineering has been declared L1:**

The company has been declared as an L1 bidder for a contract worth Rs13,188.9mn related to construction of Kondhane dam and its allied works and also an L1 bidder for a contract worth 7180mn related to hydropower project from NEEPCO.

◆ **Ami Organics' Unit II receives Japan PMDA nod for GMP compliance:**

The company announced that its Unit II manufacturing facility in Ankleshwar, Gujarat, has been granted GMP certification by Japan's Pharmaceutical and Medical Devices Agency (PMDA). The certified facility manufactures various intermediates used in APIs. This regulatory approval is a major milestone for the company, enabling it to expand its footprint in the Japanese pharmaceutical market and strengthen its positioning in other highly regulated geographies.

**Source: Media Reports**



## DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

## Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

### Compliance Officer:

Ms. Neha Oza,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

### Grievance Officer:

Email: grievancecell@progressiveshares.com

